PHE has developed and adapted many models to produce cost-effectiveness results for regulatory health technology assessment in France and other European countries. We have acquired a significant expertise in the methods and processes required to provide high-quality, robust and up to date results to decision makers.
We provide flexible methods driven by the disease landscape and existing health technology assessment frameworks, focusing on client’s needs, including critical analysis of existing models, review of literature and evidence, interaction with agencies and expert boards, models adaptation and development, redaction and review of the dossiers for the agencies.
Innovative anti-HCV treatments were expected to have a significant impact on the health insurance expenditures. PHE provided expertise and developed the cost-effectiveness dossier submitted to HAS. Outcome The models and
Tenofovir Alafenamide Fumarate (TAF), a tri-therapy antiretroviral drug used to treat HIV, was introduced as an alternative to Tenofovir Disoproxil Fumarate (TDF), an effective treatment option in lowering viral load
A cost-effectiveness dossier was submitted to the HAS for a novel innovative treatment likely to have a significant impact on the health insurance expenditure in cystic fibrosis (CF). Modelling of